<tei>
    <teiHeader>
        <fileDesc xml:id="_Ellis 2020.pdf"/>
    </teiHeader>
    <text xml:lang="en">


        <figure>

            <head>Fig. </head>
 
            <label>1 </label>
 
            <figDesc>Physician and patient response: effect of symptoms on daily<lb/> life (daily living activities/regular day-to-day life)<lb/> </figDesc>
<lb/> 
            <head>Fig. </head>
 
            <label>2 </label>
 
            <figDesc>Patient awareness of AIT: source of information</figDesc>
        </figure>


        <figure>

            <head>Fig. </head>
 
            <label>3 </label>
 
            <figDesc>Likelihood to use SLIT: allergist likelihood to prescribe versus<lb/> patient likelihood to use</figDesc>
        </figure>


        <figure>

            <head>Fig. </head>
 
            <label>4 </label>
 
            <figDesc>Likelihood to use SCIT: allergist likelihood to prescribe versus<lb/> patient likelihood to use<lb/> therapeutic options. The Canadian Society of Allergy<lb/> and Clinical Immunology recommends immunotherapy<lb/> should be considered in patients whose rhinitis and lower<lb/> airway symptoms are triggered by allergen exposure and<lb/> who have not achieved sufficient control with or have not<lb/> tolerated conventional pharmacotherapy, or do not want<lb/> to be on ongoing or long-term pharmacotherapy [6].</figDesc>
        </figure>



    </text>
</tei>

